Ichor Life Sciences Competitors and Similar CompaniesClear all

Ichor Life Sciences's competitors and similar companies include Lexicon Pharmaceuticals, Ionis Pharmaceuticals, Omega Therapeutics and Sierra Sciences.

	Ichor Life Sciences Ichor Life Sciences (formerly known as Ichor Therapeutics) is a biopharmaceutical company that develops drugs with a focus on the illnesses of aging.	Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.	Omega Therapeutics Omega Therapeutics is an epigenomic medicine company.	Sierra Sciences Sierra Sciences is a biotech company that aims to extend the human lifespan and healthspan through telomere maintenance.
Founding Date	Founding Date 2013	Founding Date 1995	Founding Date 1989	Founding Date 2017	Founding Date 1999
Type	Type Private	Type Public	Type Public	Type Public	Type Private
Tags	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma
Locations	Locations Syracuse, US HQ La Fayette, US	Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more	Locations Carlsbad, US HQ Vancouver, CA Stuttgart, DE Dublin, IE Dublin, IE Lisboa, PT London, GB see more	Locations Cambridge, US HQ	Locations Reno, US HQ
Employees	Employees 37	Employees 20216% increase	Employees 1,40231% increase	Employees 60	Employees 20
Valuation ($)	Valuation ($) N/A	Valuation ($) 737.4 m	Valuation ($) 6.3 b	Valuation ($) 68.4 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $49.8m (FY, 2025)	Revenue (est.) $943.7m (FY, 2025)	Revenue (est.) $3.1m (FY, 2023)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $274k (FY, 2025)	Cost of goods $15.9m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $49.5m (FY, 2025)	Gross profit $927.8m (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income ($50.3m) (FY, 2025)	Net income ($381.4m) (FY, 2025)	Net income ($97.4m) (FY, 2023)	Net income N/A
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 1 (FY, 2016)	Phase I Trials Products 1 (FY, 2023)	Phase I Trials Products N/A	Phase I Trials Products N/A
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 2 (FY, 2016)	Phase III Trials Products 17 (FY, 2024)	Phase III Trials Products N/A	Phase III Trials Products N/A
Funding
Total funding raised	Total funding raised $ 4.5m	Total funding raised $ 244.7m	Total funding raised N/A	Total funding raised $ 211m	Total funding raised N/A